Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...

Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...

Novartis confirmed that it has received a binding offer from Siemens Healthineers to buy its molecular imaging business for an undisclosed amount. The Swiss pharma major said Monday that the ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

(RTTNews) - Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III NATALEE trial of investigational Kisqali (ribociclib ...

Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Siemens Healthineers has agreed to buy part of a Novartis business that specialises in producing ...

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class ...